Material and Method: A total of 61 volunteer participants who had no previous history of illness or drug use were involved in this study. Of those, 20 were obese, and 41 were of normal weight. We measured the glucose and insulin values of all volunteers. We also measured the Body Mass Index (BMI) and Homeostasis Model Assessment for Insulin Resistance (HOMA IR). The impression cytology method was used to analyze the conjunctival epithelium cells, and to classify them between Grades 0 to 3 according to the Nelson criteria.
Results: There was a certain level of loss of goblet cells on the 90% level as well as squamous metaplasia (Grade 2-3) in 80% of the obese participants and impression cytology was found to be normal in only two patients. The expected results were observed in 56.1% of the control group where the squamous metaplasia rate was nearly 17% (p<0.001). 90.9% of the grade 3 patients were obese. The variables as independent predictors were found to indicate the existence of abnormal cytology in the conjunctiva at various levels; BMI (OR: 1.24; p=0.002) and HOMA IR (OR= 28.6; p= 0.001) in a Model I multivariable regression model, and the existence of obesity (OR: 11.91; p=0.002) and HOMA IR (OR= 15.08; p<0.001) in a Model II multivariable regression model.
Conclusion: Obesity was found to be a disorder that causes metaplasia in the conjunctival epithelium cells for the first time.
Furthermore, obesity may bring about complications such as cataract, macular degeneration, increased intraocular pressure, and dry eye due to Meibomian gland dysfunction [9-11]. Additionally, it has been associated with the increasing retinal nerve fiber thickness found in BMI, as well as with central macular thickness and choroidal thickness [12]. Research indicates that obesity may have certain effects on certain parts of the eye with different mechanisms. When it comes to inflammation, it would be expected that conjunctival cells may also be affected as well due to such diseases. Nevertheless, there is no clear evidence or data that shows how obesity affects either the conjunctival surface or epithelium cells.
The principle objective of this study was to evaluate the ocular surface cells in obese patients using impression cytology, as well as to determine whether obesity had caused metaplasia in these cells.
A total of 61 volunteer participants were involved in this study. Those who were under the age of 18 years, who had active or chronic eye disease, who had an ongoing or systemic disease outside of obesity, who had used systemic drugs, local eye medicine, and/or contact lenses, and/or who had previously undergone any form of eye surgery were excluded from this study. Similarly, those who had used topical cyclosporine, or who had used local or systemic non-steroid anti-inflammatory medicine or steroids over the last 6 months, alongside those who had used any topical treatments for their eyes, and had a history of herpes keratitis, blepharitis, ocular trauma, and/or non-eye surgery were also not included in this study. Furthermore, patients with the punctate epithelial erosion in the cornea were disqualified from the study. Those who did qualify as participants had neither Steven-Johnson syndrome, nor any history of thermal, chemical, or radiation damage. None of the subjects were consumers of tobacco products, alcohol, diuretics, antihistamines, vitamins, antidepressants, or anticholinergic drugs.
The glucose and insulin levels were measured from the peripheral venous blood, between 08:00 to 09:00 in the morning following a 10 hour-minimum fasting period. The Body Mass Index (BMI) was calculated as the body weight (kg) divided by the square of the height (m2). Those whose BMI was over 30 kg/m2 were accepted as obese. The Homeostasis model assessment for insulin resistance (HOMA IR) was calculated using the formula (insulin x glucose) / 405.
Schirmers test was applied to both the patients and control groups immediately following a routine eye examination. A standard kit consisting of a 5x30 mm2 filter paper was placed under the temporal part of the lower eyelid. Participants with values of less than 5 mm in the measurements after a 5-minute period were assumed to be abnormal, and were also disqualified. The stability of the tear-film layer was evaluated by determining the tear break-up time (TBUT) test. For the TBUT, a fluorescein-impregnated strip was placed in the patients lower conjunctival sac after being wetted with a non-preserved saline solution. The patient was asked to blink three to five times, and then to keep their eyes open. The time between the last blink and the appearance of the first dark dot was recorded as the TBUT. The mean of three measurements was recorded. A value of <10 s was accepted as abnormal.
The impression cytology technique was used to evaluate the conjunctival ocular surface. This technique was conducted after topical anesthesia was applied to the conjunctiva. The 4x5 mm cellulose acetate filter papers (MFS, Advantec MFS, Pleasanton, USA, pore size 0.2 μm) were placed under the superior temporal interpalpebral conjunctiva 5 mm away from the limbus. They were lightly pressed for 5 seconds and pulled away. The samples were fixed with the appropriate solutions, and tinted with dye using Papanicolaus modified version of Gills technique. The prepared samples were evaluated under a light microscope with a pathologist. The Nelson grade system was used in the classification of the results. Nelson grades conjunctival impression cytology specimens (grades 0-3) based on the appearance of the epithelial cells and the numbers of goblet cells [13].
The Nelson Classification (Figure 1A-D)
Figure 1: Grading system of impression cytology. A) Grade 0: small, ground epithelial cells have a prominent nucleus (PAS stain; x400).
B) Grade 1: the epithelial cells are slightly larger. The nuclei are smaller. Goblet cells are decreased minimally (PAS stain; x200). C) Grade
2: larger and polygonal epithelial cells (N/C ratio 1:4-1:5). Goblet cells are smaller and markedly decreased (PAS stain; x200). D) Grade
3: goblet cells have disappeared (N/C ratio 1:6) (PAS stain; x400).
Grade 0: The epithelium cells are small, oval, or rather round, and firmly bonded to one another. Their cytoplasms are eosinophilic colored. The nuclei are large and basophilic. The nucleus-to-cytoplasm rate is 1/2. The goblet cells are relatively prevalent or abundant, bulbous, and densely colored PAS (+).
Grade 1: The cytoplasm-portion of the epithelium cells is eosinophilic-colored, slightly large, and polygonal. They are about to separate from each other. The nuclei are rather small, and the nucleus-to-cytoplasm rate is 1/3. The goblet cells colored with PAS (+) are less prevalent but they are quite similar in terms of both size and shape (early loss of goblet cells).
Grade 2: The coloring of the cytoplasm varies. The epithelium cells are rather large and polygonal. They are sometimes multiple in number, and their nuclei are small. The nucleus-to-cytoplasm ratio is between 1/4 and 1/5. The prevalence of goblet cells is clearly reduced (marked decrease of goblet cells), the volume is small, cell boundaries are barely identifiable, and the PAS (+) coloring is diminished.
Grade 3: The cytoplasm portion of the epithelium cells are eosinophilic-colored, rather large, and polygonal in shape. The nucleus is lost in most of the cells. Those cells containing nucleolus are small, and have an apyknotic structure. The nucleus-to-cytoplasm ratio is 1/6, and cells that are keratinized in appearance are present. The prevalence of goblet cells is low to non-existent (total loss of goblet cells, large epithelial cells).
All specimens that were grade 1, 2 or 3 were abnormal (loss of goblet cells = abnormal cytology). In essence, grade 2 and 3 inflammations have been dubbed as squamous metaplasia due to their changing of the non-keratinized secretory epithelia into the keratinized non-secretory phase.
Statistical Analysis
The Statistical Package for Social Sciences (SPSS) for
Windows 20 (IBM SPSS Inc., Chicago, USA), alongside
the Med Calc 11.4.2 (MedCalc Software, Mariakerke,
Belgium) software programs were used for statistical
analysis. The normal distribution of the data was
evaluated with using the Shapiro-Wilk test. Values with
normal distribution were presented as a mean ± standard
deviation. Categorical variables were presented in terms of numbers and percentages. Numerical values in two groups
were compared using the Student T test. The Chi-square
and Fishers exact Chi-square tests were used to compare
the categorical data. Numerical values in the grade groups
were compared using the ANOVA test. Invariable analysis
was utilized in order to determine the effects of potential
prognostic factors on a loss of goblet cells. Significant
factors were included in the stepwise multivariate logistic
regression model, and independent predictors were
identified. The diagnostic discrimination of independent
predictors in the loss of goblet cells were examined using
ROC Curve analysis, or the area beneath the curve. In the
statistical analysis, the p<0.05 significance level with a 95%
confidence interval alongside a 5% margin of error was
considered to be statistically significant.
Table I: The distribution of clinical and demographic results by obesity presence.
There was a certain level loss of goblet cells in 90% and squamous metaplasia (Nelson grade 2-3) in 80% of obese participants and the impression cytology was found to be normal in only two patients (10%). The rate of participants without abnormal cytology was 56.1% in the control group, and the squamous metaplasia rate was nearly 17% (p<0.001). Furthermore, the average BMI, insulin, glucose and HOMA IR levels were significantly higher in the obesity group (p<0.001). When the participants were grouped according to grade level, a gradual increase in the average BMI, insulin, glucose, and HOMA IR levels was observed in association with the increase in grade levels (Table II). 90.9% (n=10) of those with grade 3 were obese. Grade 1 was found in only one of the patients belonging to the control group. Table II indicates both the demographic and clinical data associated with these grade levels.
Table II: The distribution of clinical and demographic results by grade level.
Importantly, there was a certain level of goblet cell loss found in 59% (n=36) of all of population involved in this study. Of these, 36.1% (n=13) had grade 1, 33.3% (n=12) had grade 2, and 30.6% (n=11) had grade 3 cytology. For those with abnormal cytology, the average BMI was 32.1 ± 8.3, insulin was 23.2 ± 7.7, glucose was 100.8 ± 14.7, and HOMA IR was 5.9 ± 1.7. These values were significantly higher (p<0.001) compared to those with the normal impression cytology. Table III indicates both the demographic and clinical data associated with abnormal cytology.
Table III: The distribution of clinical and demographic results by abnormal cytology presence.
There was a positive correlation between BMI and the age, alongside insulin, glucose, and HOMA IR levels within the given population. The positive correlation between the BMI level and insulin level, glucose level and HOMA IR levels remained stable in those patients with abnormal cytology; however, a significant relationship with age was lost. A correlation between the BMI versus the insulin, glucose, and HOMA IR levels was not observed in patients without abnormal cytology or obesity (Table IV).
Table IV: The distribution of clinical and demographic results by BMI level.
The likely risk factors associated with abnormal cytology were plugged into the multiple regression model. The BMI (OR=1.24; p=0.002) and HOMA IR (OR=28.6; p=0.001) were estimated as being independent predictors that indicated the presence of abnormal cytology in Model I, as observed with the multivariable regression model encompassing BMI, insulin, glucose, and HOMA IR variables. Hence, while an increase of one kg/m2 in BMI level causes the risk of goblet cell loss to increase in the conjunctiva by a factor of 1.24, a similar one unit of increase in HOMA IR level causes the risk of goblet cell loss to increase by a factor of 28.6.
The BMI (OR=11.91; p=0.002) and HOMA IR (OR=15.08; p<0.001) were estimated as being independent predictors that indicated the presence of obesity in the Model II developed with the multivariable regression model employing BMI, insulin, glucose, and HOMA IR variables. Therefore, the goblet cell loss risk was 11.91 times higher in obese patients compared to non-obese patients. It was found that a one unit of increase in HOMA IR level had caused the goblet cell loss risk to increase by a factor of 15.08 (Table V). Additionally, the diagnostic potential of the BMI, insulin, glucose, and HOMA IR levels in predicting the goblet cell loss risk was evaluated using ROC Curve analysis. Thus, the HOMA IR level had a higher diagnostic ability compared to BMI and obesity. BMI and obesity also had similar diagnostic capability (Figure 2).
Table V: The independent predictors/variables indicating the existence of abnormal cytology.
While obesity is known to be a systemic disease that affects many organs, its effects on the eyes has not yet been clearly identified. However, a handful of recent studies indicate that there is a relationship between obesity and certain types of eye diseases such as cataract, glaucoma, retinopathy, maculopathy, and dry eye disease [12-14]. A handful of different theories have been put forth that explain the mechanisms behind such complications. For example, hormonal changes such as an increase in leptin and a decrease in ghrelin, vascular changes (a decrease in vasodilator levels such as nitric oxide, a increase in vasoconstrictor levels such as Endothelin 1 and Angiotensin 2), mechanic factors (i.e. an increase in intraorbital fat tissue), and oxidative stress are likely factors that may cause the development of ocular complications in obese patients [12,15-17]. Furthermore, Baser et al., have indicated that there is a relationship between the increase of BMI and Meibomian gland dysfunction, thus causing the development of dry eye disease [9]. Another essential mechanism is the activation of systematic chronic inflammation and immune system [4-7]. For the first time, Hotamisligil et al., has shown an increase of TNF-alpha expression in the fat tissue of obese patients, which has a direct influence on insulin resistance [18]. A number of other studies indicated that increased adipose tissue was shown to cause up-regulation in genes encoding inflammatory factors, activation in c-Jun N-terminal kinase (JNK) and nuclear factor-kappa B (NF- κB) pathways, and also increase in production of some cytokines and chemokines [4-7]. Although the main source of inflammation is adipose tissue, it was shown that the liver, pancreas, brain, and muscle tissue also contribute to the inflammatory response [19]. The primary markers influencing the inflammation include coagulative factors such as white blood cells, fibrinogen, and plasminogen activator inhibitors (PAI-1); acute phase proteins such as serum Amyloids A (SAA); and pro-inflammatory cytokines and chemokines such as TNF-alpha, IL-1β and IL-6 (20-25). The inflammatory response moderately and frequently endures as long as it is not induced with a stimulant such as trauma or acute immune response [19]. The two pathologic processes causing loss of goblet cells in squamous metaplasia include the loss of vascularization and intense inflammation [26]. A number of matrix protease inhibitors resemble anti-inflammatory factors such as the T lymphocytes, IL-1 receptor antagonists, TGF-β2, and tissue inhibitors of metalloproteinase-1 (TIMP-1) and all play important roles in the immune balance of the ocular surface [27]. When all of the aforementioned mechanisms are considered together, it can be thought that the inflammatory response developing in obesity may destroy the immune system balance and thus cause the development of inflammation on conjunctival epithelium cells. This may be attributed to the results of earlier research regarding obesity causing inflammation on the ocular surface cells of patients with certain autoimmune and inflammatory diseases such as autoimmune thyroid disease, diabetes mellitus, inflammatory colon disease, and chronic kidney disease [28-31]. The development of dry eye disease was found to be responsible for the inflammation caused by some of these diseases. In our study, however, dry eye disease was either excluded or disqualified as based on Schirmers test. Although the primary reason for the development of squamous metaplasia is thought to be systemic inflammation, the hormonal and vascular changes may have either caused or contributed to the development of this situation.
Obesity is the main reason behind the lessening in insulin vulnerability, thus resulting in insulin resistance (IR) occurring in most of the patients [32-34]. It is thought that insulin resistance plays an important role in inflammation [35,36]. The existence of the relationship between IR and the immune system was demonstrated for the first time through studies showing the increase of insulin resistance based on infections [37,38]. These studies have also shown that there is a positive correlation between insulin resistance and pro-inflammatory cytokine levels [20,21,39]. We have found a strong relationship between the worsening of the grade in conjunctiva and IR (insulin level and HOMA IR index). In other words, the existence as well as strength of insulin resistance appears to be an independent risk factor for squamous metaplasia.
Glucose metabolism disorders are also frequently associated with obesity [40]. DM is a disease that develops due to systemic inflammation [40]. Little in the way of research exists that shows the increase of the frequency of conjunctival squamous metaplasia in diabetes, and what exists only shows that this is related to the poor control of diabetes [41-43]. There was no diabetes in our study; however, we did determine that there is a relationship between glucose levels and the development of squamous metaplasia.
The formation or origination mechanism of the conjunctival squamous metaplasia developed in most systemic diseases such as obesity, DM and IR has not yet been clearly understood. However, numerous studies have claimed that the most important mechanism is dry eye disease, which is caused by the effect of the tear gland. In addition, there are also other important studies showing that other factors such as inflammation (which directly affect the epithelium cells) may play an important role in the development of the disease [43]. Our study is crucial in that not only does it indicate directly the relationship between obesity and conjunctival squamous metaplasia for the first time, but it also supports the idea that other factors such as primary systemic inflammation alongside dry eye disease may also play an important role in its development mechanism.
There are, however, some limitations to our study. The number of patients participating in the study was insufficient. Furthermore, we did not examine data such as systemic inflammation markers or leptin and ghrelin levels, which are more objectively able to indicate the relationships of squamous metaplasia with systemic inflammation and other mechanisms.
In conclusion, our study is the first to indicate that the ocular surface cells can be affected by obesity. Such situations may lead to certain vision problems in conjunction with other obesity-related ocular complications. Routine eye examinations therefore need to be conducted, whereby ocular surface cells are evaluated carefully during the follow up of obese patients, this in turn requiring a multidisciplinary approach. More comprehensive future research into this subject seems to be necessary.
CONFLICT of INTEREST
The authors report no conflicts of interest. The authors
alone are responsible for the content and writing of the
paper.
1) Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity
and trends in the distribution of body mass index among US
adults, 1999-2010. JAMA. 2012;307:491- 7.
2) Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK,
Paciorek JC, Singh GM, Gutierrez HR, Lu Y, Bahalim AN,
Farzadfar F, Riley LM, Ezzati M. National, regional, and global
trends in body-mass index since 1980: Systematic analysis of
health examination surveys and epidemiological studies with 960
country-years and 9.1 million participants. Lancet. 2011;377:557-67.
3) Hotamisligil GS. Inflammation and metabolic disorders. Nature
2006;444:860-7.
4) Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin
resistance. J Clin Invest. 2006;116:1793-801.
5) Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory
disease. Nat Rev Immunol. 2011;11:98-107.
6) Chawla A, Nguyen KD, Goh YP. Macrophage-mediated
inflammation in metabolic disease. Nat Rev Immunol.
2011;11:738-49.
7) Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in
inflammation and metabolic disease. Nat Rev Immunol.
2011;11:85-97.
8) Chang RC, Shi L, Huang CC, Kim AJ, Ko ML, Zhou B, Ko GY.
High-fat diet-induced retinal dysfunction. Invest Ophthalmol
Vis Sci. 2015;56: 2367-80.
9) Baser G, Yıldız N, Calan M. Evaluation of meibomian gland
dysfunction in polycystic ovary syndrome and obesity. Curr Eye
Res. 2017;42: 661-5.
10) Kim HT, Kim JM, Kim JH, Lee JH, Lee MY, Lee JY, Won YS,
Park KH, Kwon HS. Relationships between anthropometric
measurements and intraocular pressure: The Korea National
Health and Nutrition Examination Survey. Am J Ophthalmol.
2017;173: 23-33.
11) Tiruvalluru M, Ananthathmakula P, Ayyalasomayajula
V, Nappanveettil G, Ayyagari R, Reddy GB. Vitamin A
supplementation ameliorates obesity-associated retinal
degeneration in WNIN/Ob rats. Nutrition. 2013;29: 298-304.
12) Dogan B, Kazim EM, Dogan U, Habibi M, Bulbuller N, Turgut
Coban D, Bulut M. The retinal nerve fiber layer, choroidal
thickness, and central macular thickness in morbid obesity: An
evaluation using spectral-domain optical coherence tomography.
Eur Rev Med Pharmacol Sci. 2016;20: 886-91.
13) Singh R, Joseph A, Umapathy T, Tint NL, Dua HS. Impression
cytology of the ocular surface. Br J Ophthalmol. 2005;89:1655-9.
14) Cheung N, Wong TY. Obesity and eye disease. Surv Ophthalmol.
2007;52:180-95.
15) Butt Z, Obrien C, Mckillop G, Aspinall P, Allan P. Color Doppler
imaging in untreated high-and normal -pressure open-angle
glaucoma. Invest Ophthalmol Vis Sci. 1997;38:690-6.
16) Gherghel D, Orgul S, Gugleta K, Gekkieva M, Flammer J.
Relationship between ocular perfusion pressure and retrobulbar
blood flow in patients with glaucoma with progressive damage.
Am J Ophthalmol. 2000;130:597-605.
17) Ferreira SM, Lerner SF, Brunzini R, Evelson PA, Llesuy SF.
Oxidative stres markers in aqueous humor of glaucoma patients.
Am J Ophthalmol. 2004;137:62-9.
18) Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM.
Increased adipose tissue expression of tumor necrosis factoralpha
in human obesity and insulin resistance. J Clin Invest.
1995;95:2409-15.
19) Gregor MF, Hotamisligil GS. Inflammatory mechanisms in
obesity. Annu Rev Immunol. 2011;29: 415-45.
20) Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a
disease of the innate immune system: Association of acutephase
reactants and interleukin-6 with metabolic syndrome X.
Diabetologia. 1997;40:1286-92.
21) Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive
protein in healthy subjects: Associations with obesity, insulin
resistance, and endothelial dysfunction: A potential role for
cytokines originating from adipose tissue? Arterioscler Thromb
Vasc Biol. 1999;19:972-8.
22) Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M,
Vidal H, Hainque B. Elevated levels of interleukin 6 are reduced
in serum and subcutaneous adipose tissue of obese women after
weight loss. J Clin Endocrinol Metab. 2000;85:3338-42.
23) Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton
E, Marcovina S, Mather K, Orchard T, Ratner R, Barrett-Connor
E. Intensive lifestyle intervention or metformin on inflammation
and coagulation in participants with impaired glucose tolerance.
Diabetes. 2005;54:1566-72.
24) Bruun JM, Helge JW, Richelsen B, Stallknecht B. Diet and
exercise reduce low-grade inflammation and macrophage
infiltration in adipose tissue but not in skeletal muscle in severely
obese subjects. Am J Physiol Endocrinol Metab. 2006;290:961-7.
25) Belalcazar LM, Haffner SM, Lang W, Hoogeveen RC, Rushing J,
Schwenke DC, Tracy RP, Pi-Sunyer FX, Kriska AM, Ballantyne
CM. Lifestyle intervention and/or statins for the reduction of
C-reactive protein in type 2 diabetes: From the look AHEAD
study. Obesity. 2013;21:944-50.
26) Tseng SC, Hirst LW, Maumenee AE, Kenyon KR, Sun TT, Green
WR. Possible mechanisms for the loss of goblet cells in mucindeficient
disorders. Ophthalmology. 1984;91:545-52.
27) Baudouin C, Irkeç M, Messmer EM, Benítez del Castillo JM,
Bonini S, Figueiredo FC, Geerling G, Labetoulle M, Lemp
M, Rolando M, Van Setten G, Aragona P. Clinical impact of
inflammation in dry eye disease: Proceedings of the ODISSEY
group meeting. Acta Ophthalmol. 2018;96:111-9.
28) Kesarwani D, Rizvi SWA, Khan AA, Amitava AK, Vasenwala
SM, Siddiqui Z. Tear film and ocular surface dysfunction in
diabetes mellitus in an Indian population. Indian J Ophthalmol.
2017;65: 301-4.
29) Demir N, Altay M, Özer E, Ünlü N, Duranay M, Üstün H,
Duman S. Duration of renal failure as risk factor for conjunctival
squamous metaplasia. Acta Cytol. 2008; 52:309-12.
30) Uzel MM, Citirik M, Kekilli M, Cicek P. Local ocular surface
parameters in patients with systemic celiac disease. Eye.
2017;31:1093-8.
31) Kocabeyoglu S, Mocan MC, Cevik Y, Irkec M. Ocular surface
alterations and in vivo confocal microscopic features of corneas
in patients with newly diagnosed graves disease. Cornea.
2015;34:745-9.
32) Mohanraj L, Kim HS, Li W, Cai Q, Kim KE, Shin HJ, Lee YJ, Lee
WJ, Kim JH, Oh Y. IGFBP-3 inhibits cytokine-induced insulin
resistance and early manifestations of atherosclerosis. PLoS
ONE. 2013;8(1): e55084.
33) Daniele G, Mendoza RG, Winnier D, Fiorentino TV, Pengou
Z, Cornell J, Andreozzi F, Jenkinson C, Cersosimo E, Federici
M, Tripathy D, Folli F. The inflammatory status score including
IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin
underlies whole-body insulin resistance and hyperglycemia in
type 2 diabetes mellitus. Acta Diabetol. 2014;51:123-31.
34) Osborn O, Olefsky JM. The cellular and signaling networks
linking the immune system and metabolism in disease. Nat Med.
2012;18:363-74.
35) Chen L, Chen R, Wang H, Liang F. Mechanisms linking
inflammation to insulin resistance. Int J Endocrinol.
2015;2015:508409.
36) Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N.
Inflammation as a link between obesity, metabolic syndrome and
type 2 diabetes. Diabetes Res Clin Pract. 2014:105: 141-50.
37) Clowes GH Jr, Martin H, Walji S, Hirsch E, Gazitua R,
Goodfellow R. Blood insulin responses to blood glucose levels in
high output sepsis and septic shock. Am J Surg. 1978:135:577-83.
38) Wichterman KA, Chaudry IH, Baue AE. Studies of peripheral
glucose uptake during sepsis. Arch Surg. 1979;114:740-5.
39) Phillips CM, Perry IJ. Does inflammation determine metabolic
health status in obese and nonobese adults? J Clin Endocrinol
Metab. 2013;98:1610-9.
40) Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI,
Donato KA, Fruchart JC, James WP, Loria CM, Smith SC
Jr. Harmonizing the metabolic syndrome: A joint interim
statement of the International Diabetes Federation Task Force on
Epidemiology and Prevention; National Heart, Lung, and Blood
Institute; American Heart Association; World Heart Federation;
International Atherosclerosis Society; and International
Association for the Study of Obesity. Circulation. 2009;120:
1640-5.
41) Yoon KC, Im SK, Seo MS. Changes of tear film and ocular surface
in diabetes mellitus. Korean J Ophthalmol. 2004:18:168-74.